Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Relmada Therapeutics, Inc. (RLMD) had Weighted-Average Shares Outstanding (Diluted) of 112.38M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-12.91M |
|
-- |
|
-- |
|
$15.01M |
|
$-15.01M |
|
$2.10M |
|
$-12.91M |
|
$-12.71M |
|
$-12.91M |
|
$-12.91M |
|
$-12.91M |
|
$-12.71M |
|
$-15.01M |
|
$-15.01M |
|
112.38M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
112.38M |
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$219.04M |
|
-- |
|
$0.02M |
|
$219.06M |
|
$7.42M |
|
-- |
|
$5.08M |
|
$12.50M |
|
$206.56M |
|
$206.56M |
|
$206.56M |
|
106.67M |
|
| Cash Flow Statement Financials | |
$-24.67M |
|
$-117.64M |
|
$150.15M |
|
$3.50M |
|
$11.33M |
|
$7.84M |
|
$5.88M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
29.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.67M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.25% |
|
-6.25% |
|
-5.90% |
|
-6.25% |
|
$1.94 |
|
$-0.22 |
|
$-0.22 |
|